BTIG analyst Jeet Mukherjee raised the firm's price target on Monopar Therapeutics to $117 from $104 and keeps a Buy rating on the shares. Monopar has an improved regulatory outlook ahead of its planned NDA submission for ALXN1840 in Wilson's disease, supported by recent FDA signals suggesting greater flexibility for rare disease approvals based on a single high-quality Phase 3 trial plus confirmatory evidence, alongside broader regulatory reversals in the rare disease space, the analyst tells investors in a research note.
